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Acute liver failure as life threatening condition comprises a difficult diagnostic situation
to evaluate potential outcomes and therapeutic options. Thus, prognostic indicators are
urgently needed for evaluation of progression of liver injury, clinical outcome, prognosis,
and for therapeutic response. Recently, circulating microRNA, in particular miR-122, was
described as a potential biomarker of acute liver injury after intoxication of mice. Circulating
microRNA (miRNA) molecules are very stable and RNase-resistant due to protein
aggregation and vesicle enclosure. Since miRNA species are known to be associated with
chronic liver damage or with liver cancer, circulating miRNA patterns are suggested to
serve also as reporters for progression of acute liver failure. miRNA profiling analyses using
PCR arrays or next generation sequencing, may achieve identification of miRNA species
that are linked to the rapid progression of acute liver injury, to the outcome of liver failure,
or to the therapeutic response. Therefore, circulating miRNAs are promising, non-invasive
biomarkers of future diagnostic approaches. However, normalisation of circulating miRNA
levels is essential and further standardisation of miRNA quantification assays is needed.
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INTRODUCTION
Acute liver failure is a life-threatening liver disease characterized
by a rapid and fulminant loss of liver function. Common causes
of acute liver failure are viral hepatitis infection, mainly hepatitis
A and B, and drug-induced liver intoxication (Canbay et al., 2005;
Hadem et al., 2008; Ichai and Samuel, 2008, 2011; Lee, 2012).
Acute liver failure demands urgent medical care, but initial symp-
toms of acute liver failure such as diarrhea, fatigue, and loss of
appetite are rather unspecific and difficult to interpret (Renner,
2007). Rapid progression of liver malfunction is then accom-
panied by serious symptoms as ascites, hepatic encephalopathy,
and coma. Sometimes, the acute liver failure can be reversed by
valiant clinical intervention, but in many cases liver transplanta-
tion might be the only option of cure (Bernal et al., 2008; Ichai
and Samuel, 2008; Lee, 2012). Thus, prognostic indicators are
urgently needed for evaluation of progression of liver injury, clin-
ical outcome, prognosis, and for therapeutic response. Recently,
circulating microRNA is described as a novel tool to diagnose
and monitor various diseases [summarized by Cortez and Calin
(2009)].
MicroRNAs (miRNAs) are short noncoding, endogenous
RNAs that regulate posttranscriptional gene expression by either
RNA interference or inhibition of translational initiation and
elongation (Bartel, 2004). Therefore, miRNAs are implicated
in a widespread variety of cellular processes like differentia-
tion, cell proliferation, and apoptosis (Miska, 2005; Bushati and
Cohen, 2007). In human, more than thousand miRNAs are
known (Kozomara and Griffiths-Jones, 2011). Mature miRNAs
are formed in a step-wise process from larger primary transcripts
(pri-miRNA), which are further processed, folding to hairpin
structured precursor miRNA (pre-miRNA). The pre-miRNAs are
exported from the nucleus, serving as substrates for the Dicer
family of RNase III enzymes. One strand of the resulting short
dsRNA guides the RNA-induced silencing complex (RISC) to its
target mRNA (Zhao and Srivastava, 2007). Then, perfect com-
plementary interaction of miRNAs with the untranslated region
(UTR) of transcripts results in transcript degradation, whereas
imperfect base pairing of miRNAs with the targeted UTR leads to
translational repression (Zhao and Srivastava, 2007; Bartel, 2009).
In addition to the cellular function of miRNA in posttran-
scriptional gene repression, recent data collect evidence that
miRNA also occur in extracellular compartments (Hunter et al.,
2008; Mitchell et al., 2008). In our present review, we summa-
rize the perspectives of circulating miRNAs to function as novel
promising biomarkers of acute hepatitis.
DYSREGULATION OF HEPATIC miR-122 AFTER LIVER INJURY
miRNA expression profiles appear to be tissue-specific. Thus,
miR-122 is highly expressed in hepatocytes, due to its liver-
specific transcriptional regulation by hepatocyte nuclear tran-
scription factors (HNF1α, HNF3β, and HNF4α) (Coulouarn
et al., 2009; Xu et al., 2010). miR-122, comprising approximately
70% of total miRNA in the healthy liver, takes part in liver-
specific functions such as cholesterol metabolism (Esau et al.,
2006; Jopling, 2012). Interestingly, miR-122 is transcribed in a cir-
cadian fashion affecting gene expression pattern of a wide range
of proteins (Gatfield et al., 2009). Whereas miR-122 interaction
with the 3′ untranslated region (UTR) of various transcripts
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leads to gene repression, miR-122 binding to two target sites in
the 5′-UTR of the HCV genome results in HCV-RNA genome
stabilization and enhanced replication. Hence, the liver-specific
miR-122 may contribute to HCV liver tropism at the level of
translation (Henke et al., 2008; Jopling, 2008).
Dedifferentiation of hepatocytes during hepatocellular car-
cinogenesis is associated with the loss of miR-122 (Coulouarn
et al., 2009; Burchard et al., 2010; Negrini et al., 2011).
In addition, during, both, acute and chronic liver damages
in response to various noxa such as viral infection, drug
or alcohol intoxication, or heriditary disorders, miR-122 is
markedly decreased in the injured liver. Thus, after non-
alcoholic fat liver diseases (Cheung et al., 2008) as well as
after chronic hepatitis C infection reduced hepatic miR-122
levels were observed (Sarasin-Filipowicz et al., 2009; Morita
et al., 2011). However, whereas miRNA is decreased in the
injured liver, recent reports pointed to increased levels of cir-
culating miR-122 in the blood stream after acute liver injury-
induced by paracetamol intoxication of mice (Wang et al.,
2009).
miRNA RELEASED INTO THE BLOOD STREAM AFTER LIVER
DISEASE
In serum from human patients suffering from prostate cancer, it
was first described that miRNA occur also extracellularily (Hunter
et al., 2008; Mitchell et al., 2008). Circulating miRNA are highly
stable in serum and also RNase resistant (Figure 1A), due to
protein aggregation and vesicle enclosure (Mitchell et al., 2008;
Cortez and Calin, 2009; Chen et al., 2010). As vesicular structures
embedding extracellular miRNA, apoptotic bodies, microvesicles
(Hunter et al., 2008; Skog et al., 2008), and exosomes (Taylor
and Gercel-Taylor, 2008) have been discussed (Figure 1B). Due
to their high stability, they are ideal candidates considered as
non-invasive diagnostic markers indicating progression and ther-
apy outcome of disease. Accordingly, circulating miRNAs were
detected in some other tumorigenic diseases such as ovarian
(Lodes et al., 2009; Resnick et al., 2009), lung, and colorectal
cancer (Chen et al., 2008; Ng et al., 2009) (for review please see
Cortez and Calin, 2009). Furthermore, Vasilescu et al. revealed
circulating miR-150 as a new prognostic marker of patients with
sepsis andWang et al. described prominent upregulation of serum
FIGURE 1 | Highly stable miRNA is released from hepatocytes after
acute liver damage. (A) High stability of endogenous miRNA in serum
samples. Non-human chemically synthesized miRNA was added to human
serum samples. Then the samples were incubated for 0.5 up to 48 h at room
temperature (RT). Endogenous miR-122 (red) and spiked RNA (gray) was
quantified by Real Time PCR, demonstrating high stability of endogenous
miR-122, but degradation of the added non-human RNA. (B) Vesicular
enclosure of circulating serum miRNA. Vesicles of around 50 nm in diameter
are found in the serum, as shown by uranyl acetate negative-staining and
subsequent transmission electronmicroscopy (TEM) (B). The vesicle fraction
carries miRNA as proven by Real Time PCR (Hunter et al., 2008; Skog et al.,
2008; Chen et al., 2010). Interestingly, Bala et al. pointed out that after acute
paracetamol intoxication in mice, circulating miR-122 is not predominantly
associated to vesicles, but to protein aggregates (Bala et al., 2012).
(C) Hepatic miRNA release after acute liver injury. miRNA is released from
hepatocytes after acute liver damage. Interestingly, circulating miR-122 levels
are increased in serum samples before levels of transaminases (ALT) were
elevated. Therefore, miR-122 might not only be released after hepatocellular
damage and death (2), but also by other mechanisms e.g., inflammatory
processes, not yet described (1).
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miR-122 and miR-192 after acute hepatic intoxication by parac-
etamol in mice (Wang et al., 2009). In addition to miR-122
and miR-192, Zhou et al. identified miR-21, miR-223, miR-26a,
miR-27a, and miR-801 in serum of patients with hepatocellular
carcinoma (HCC) and proposed this miRNA panel as predictive
markers of HCC. A comprehensive study on a wide cohort of
patients with HBV or HCV based HCC revealed that high miR-
25, let7f and primary miR-375 profiles only occurred in HCC-
positive patients. Herein, increased miR-375 levels are shown to
be specifically associated to HBV positive HCC (Li et al., 2010).
Importantly, miRNA panels in serum could not only be
applied to differentiate between HCC and normal healthy donors,
but also between HCC and cirrhosis (Zhou et al., 2011). Although
miR-122 quantification of 68 serum samples of chronic HCV-
positive patients was not normalized, the findings of Bihrer
et al. definitively demonstrate that miR-122 correlated with ala-
nine aminotransferase (ALT) values indicating liver inflammatory
activity (Bihrer et al., 2011). Thus, circulating miRNAs are pro-
posed as new biomarkers not only for tumorigenic, but also for
inflammatory liver diseases.
EXTRACELLULAR miRNAs IN THE BLOOD STREAM ARE
PROMISING BIOMARKES OF ACUTE HEPATITIS
Previous findings in mice after acute intoxication revealed that
miR-122 increased markedly in serum samples before liver
transaminases were raised (Wang et al., 2009; Zhang et al.,
2010). This is of particular interest, because miRNA might
not only be released by hepatocellular destruction processes,
but also by active secretory delivery into the blood stream
(Figure 1C). Consequently, early increased levels of serum miR-
122 in response to inflammatory stimuli have to be considered
as better indicators of liver failure than determination of liver-
specific enzymes such as ALT (Zhang et al., 2010; Wang et al.,
2012). Interestingly, Bala et al. found that after acute paracetamol
intoxication of mice, miR-122 and miR-155 were predominantly
associated in protein aggregates, whereas after alcoholic liver
disease these two miRNAs were mainly found in the vesicular
fraction (Bala et al., 2012). In addition, Novellino et al. suggested
that in 13 serum samples of patients with HBV infection, miRNA
is mainly complexed with the Ago2 protein, which in turn binds
the hepatitis B surface protein (Novellino et al., 2012).
In addition to the experiments on acutely intoxicated mice,
first data are now available on human, showing high miR-122
levels after acute hepatitis in man (Starkey Lewis et al., 2011;
Ding et al., 2012). The extracellular miR-122 levels in serum from
patients with acetaminophen based acute liver injury were nor-
malized using small nuclear (sn)U6 spliceosomal RNA which is
so far themost commonly applied internal reference of circulating
miRNA quantification (Table 1). Though snU6 RNA is proposed
to be also released into the blood stream after cellular damage
Table 1 | miRNAs as potential biomarkers for liver disease.
Potential miRNA
biomarker
Human liver
disease
Normalisation Detection/quantification
method
Message Referencesb
High: miR-21,
miR-192, −801
HBV HCC
HBV chronic
miR-1228 Microarray, Real Time PCR Differentiation between
healthy donors, chronic
Zhou et al., 2011
Low: miR-26a, −27a,
miR-122, −223,
(N ∼ 1000) HBV, and HCC
High: miR-25, −92a,
let7f, miR-375
HBV chronic,
HCC (N ∼ 150)
/ NGS, Real Time PCR miR-375 is HBV specific
and a HCC predictor
Li et al., 2010
High: miR-122,
miR-21, 223
HBV chronic,
HCC (N ∼ 150)
miR-181aa
miR-181ca
Relative Real Time PCR Increase in chronic HBV
and HCC
Xu et al., 2011
High: miR-122 HBV chronic
(N = 83)
U6 RNA Relative Real Time PCR Increase of miR-122 Zhang et al., 2010
High: miR-885-5p HBV chronic,
cirrhotic, HCC
(N > 100)
U6 RNA Relative Real Time PCR Increase in chronic,
cirrhotic HBV and HCC
Gui et al., 2011
High: miR-122 HCV chronic
(N = 68)
/ Relative Real Time PCR Increase correlated
with ALT
Bihrer et al., 2011
High: miR-571 Chronic HCV and Spike-in RNA Relative Real Time PCR miR-571 reflects Roderburg et al., 2012
Low: miR-652 alcohol (N = 67) progression
High: miR-122, −34 HCV chronic
(N = 34), NAFLD
(N = 35)
Spike-in RNA Absolute Real Time PCR Correlation with ALT,
inflammatory activity
and fibrosis
Cermelli et al., 2011
High: miR-122, −192 Acute (POD)
(N = 53)
U6 RNA Real Time PCR Increase correlated
with ALT
Starkey Lewis et al.,
2011
aaccording to geNorm; POD: acetominophen overdose.
bUnfortunately, we could not refer to all literature.
miRNA shown in bold: miRNA identified in serum samples by various reports.
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FIGURE 2 | Identification of predictive miRNAs in acute hepatitis.
(A) Retrospective studies of miRNA pattern during acute hepatitis (Discovery).
For identification of putative miRNA biomarkers, well defined serum or
plasma samples of patients suffering from acute hepatitis are used for total
RNA isolation by means of a phenol-based extraction method. In order to
normalize the levels of circulating miRNAs spike-in RNA, highly dissimilar to
human miRNAs e.g., C. elegans, SV-40 virus, or Arabidopsis thaliana or an
artificial miRNA sequence, should be added to the sample before extraction.
Quantitative miRNA pattern analyses can be performed by next generation
sequencing (NGS) or by PCR array analyses. The correlation of miRNA
profiles with clinical parameters, with disease progression and outcome will
suggest a panel of miRNAs as putative indicators of hepatitis. (B) Analysis of
selected miRNAs during acute hepatitis (Training and Validation). miRNA,
identified by NGS or PCR array screening approaches, have to be validated on
a wide cohort of patients with acute hepatitis by retrospective and
prospective studies. For validation and future diagnostic analyses, selected
miRNA are quantified by Real Time PCR (Figure 3). Normalisation of miRNA
levels by spike-in RNA is essential as described in the text.
FIGURE 3 | miRNA quantification by Real Time PCR. For PCR amplification
the short miRNA molecules have to be prolonged first. Elongation of miRNA
takes place simultaneously to the reverse transcription reaction by hair
looped primer sets recognizing the miRNA (I) (Chen et al., 2005) or by
unspecific polyadenylation of RNA molecules (II) (Shi and Chiang, 2005).
Whereas in the hairpin-loop primed cDNA two specific primers are used for
PCR amplification (I), polyadenylated RNA, which is reversely transcribed by
an oligo-dT primer carrying an universal template sequence, is amplified by
the universal and only one specific primer. Real-time monitoring can be
performed by integration of fluorochrome labeled probes or by interaction of
fluorescent dyes with the templates. Both methods (I and II) are highly
effective, though having different advantages. Whereas the usage of
miRNA-specific hairpin-looped primers results in very robust and highly
specific miRNA quantification, polyadenylation provides the opportunity to
use cDNA from one reverse transcription reaction for analyses of several
miRNAs.
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including liver parenchymal injury, this data interpretation may
provide a primary impression of the role of miR-122 in human
acute liver failure. However, Ji et al. found no change of miR-122
in 21 patients with HBV-induced acute-on-chronic liver failure,
whereas miR-122 in patients with chronic HBV infection was even
decreased in comparison to 12 healthy controls (Ji et al., 2011).
These conflicting results might be due to diversity of study designs
and technical approaches.
FOR PREDICTIVE USE, STANDARDISATION IN miRNA
QUANTIFICATION IS NEEDED
Different methods are used to identify the pattern of miRNA in
serum. Due to the very high sensitivity required for detection of
circulating miRNA, Real Time PCR approaches are mostly car-
ried out for screening as well as for validation of miRNA levels
(Figure 2). Since miRNA are small templates, PCR needs a care-
ful primer design and an elongation step of miRNA templates has
to be combined to the reverse transcription before PCR amplifica-
tion is started (Figure 3). For elongation of miRNA targets, either
polyadenylation of miRNA is carried out (Shi and Chiang, 2005)
or hairpin-looped primers are applied to the reverse transcrip-
tion step leading to elongation of cDNA by the hairpin sequence
(Chen et al., 2005) (Figure 3).
However, next generation sequencing (NGS) is also a valuable
method to detect the pattern of circulating miRNAs followed by
PCR quantification to validate data on a wide cohort of patients
(Figure 2).
Although miR-122, miR-192, miR-21, and miR-34a are shown
by most reports to be increased after experimental or human
liver injury (Table 1), high variance and conflicting data exist
about miRNA incidence in the blood stream upon differ-
ent liver diseases. Kim et al. pointed out, that blood com-
ponents that are co-purified with miRNA from serum or
plasma highly affect efficiency of miRNA quantification by PCR
(Kim et al., 2012). It is well-known that anti-coagulants in
blood samples strongly inhibit Taq-polymerase, but plasma or
serum sample volume, time until serum or plasma is pre-
pared might also affect miRNA accessibility by Real Time PCR
assays.
In addition, the accuracy of extracellular miRNA quantifi-
cation highly depends on normalisation using an appropriate
reference RNA. Thus, Xu et al. identified increased levels of cir-
culating miR-122 and mir-92a as putative markers of chronic
HBV infection after normalisation to endogenous miR-181 val-
ues, whereas Ji et al. observed decreasing levels of both miRNA
after normalisation using snU6-RNA (Ji et al., 2011; Xu et al.,
2011). snU6-RNA is mostly used as a reference. It is ubiquitously
expressed in cells, but highly differs in the blood stream of differ-
ent individuals (Qi et al., 2012). Furthermore, Ding et al. found
that snU6-RNA is decreased after hepatocarcinogenesis (Ding
et al., 2012). Hence, an internal standard for miRNA quantifi-
cation is missing, so far. Therefore, the application of spike-in
RNA is recommended in order to normalize errors in sample
handling and extraction (Figure 2). Though miRNA are very sta-
ble molecules in serum or plasma, for better comparability and
reproducibility in future studies, a well-standardized protocol is
needed, in order to evaluate miRNAs as biomarkers for acute
hepatitis.
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